Xin Du

Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study

Yu Wang, Xuejie Jiang, F. Huang, 2023, Journal of Internal Medicine.

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Dajun Yang, Y. Zhai, Q. Niu, 2023, Blood.

Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy

Hua Jin, Zhiqiang Sun, Guopan Yu, 2024, Cancer medicine.

18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China

Yirong Jiang, Jin Lou, Xin Du, 2023, Frontiers in medicine.

Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment

A. Qin, Toshiaki Sato, S. Suo, 2024, Journal of hematology.

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

Xuejie Jiang, L. Xuan, Hua Jin, 2023, Blood.